Szívelégtelenség: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• SGLT2 29
• GLP-1 6
• TTR 10
• AMPK 0
• NLRP3 0
• NRF2 0
• PI3K 0
• PPAR 0
• AKT 0
• mTOR 0
• HER2 2
• STAT3 0
• TP53 0
• MAPK 0
• SIRT1 0
• STING 0
• EGFR 0
• GIP 4
• HIF-1 0
• PCSK9 0
• DPP-4 0
• VEGF 0
• HMGB1 0
• IL-6 0
• CTNNB1 0
• TNF 0
• YAP 0
• PINK1 0
• ERK 0
• GPX4 0
• JAK 0
• TLR4 0
• IL-1 0
• JNK 0
• MEK 1
• HSP90 0
• DMD 0
• IL-17 0
• MMP-9 0
• PD-1 0
• CD40 0
• COX-2 0
• HDAC 0
• PD-L1 0
• TFEB 0
• ABL1 0
• APOE 0
• AR 0
• BCL-2 0
• FTO 0
• METTL3 0
• MYC 0
• PTEN 0
• ACE2 0
• BDNF 0
• BRAF 0
• BRD4 0
• BTK 0
• CDK4/6 0
• FAK 0

19+ intézményből 19, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrative Modeling of Autonomic dysfunction and Cardiac arrhyThmogenesis (IMpACT)

  Politecnico di Milano· Milano, Olaszország· EU contribution 193 643 EUR· until 2029. aug.· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Bioinspired Modulation of Cardiac Troponin I Splicing to Treat Diastolic Dysfunction (TROPOSplice)

  Centro Nacional de Investigaciones Cardiovasculares Carlos Iii (F.s.p.)· Madrid, Spanyolország· EU contribution 1 499 625 EUR· until 2032. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  From n=1 to many: Scaling-up gene editing for future heart therapies (ONE2MANY)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Németország· EU contribution 1 499 468 EUR· until 2031. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A computational framework for personalising atrial fibrillation treatment to minimise heart failure risk (AFHF-TAILOR)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Svájc· EU contribution 292 119 EUR· until 2028. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-CSA

  RAPid TranslatiOnal Research - Heart Failure (RAPTOR-HF)

  Uniwersytet Medyczny Im Piastow Slaskich We Wroclawiu· Wroclaw, Lengyelország· EU contribution 15 000 000 EUR· until 2032. dec.· 3 countries

5 of 84 running projects, newest first. Listed amounts together: 318,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  SGLT2-Inhibitors for Sleep Apnea in Heart Failure

  NCT04640493· Columbia University· Frissítve: 2024. máj. 13.

  “Lack of enrollment”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency

  NCT05737186· Peking University People's Hospital· Frissítve: 2024. ápr. 30.

  “Double blind packaged drug is up to expiration date”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

  NCT07572032· Kyungsub Song· Forrás

• Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves

  NCT07610174· Kafrelsheikh University· Forrás

• Implementation of SGLT-2 Inhibitors in Patients With Heart Failure Through a New Digital Strategy

  NCT05890131· Morten Schou· Forrás

• SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

  NCT05057806· The University of Texas Health Science Center at San Antonio· Forrás

• Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure

  NCT07478575· University Medical Centre Ljubljana· Forrás

• Dapagliflozin for Cardio-renal Protection After ICU Discharge

  NCT07025629· Assistance Publique - Hôpitaux de Paris· Forrás

• Early Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department

  NCT07392788· Centre Hospitalier Universitaire de Besancon· Forrás

• Ketones, SGLT2, HFrEF

  NCT06229678· The University of Texas Health Science Center at San Antonio· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 17
• Organoids 5
• Mendelian Randomization Analysis 79
• CRISPR-Cas Systems 7
• Gene Expression Profiling 71
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 10
• Proteomics 108
• Metabolomics 64
• Mass Spectrometry 5
• Flow Cytometry 10
• Immunohistochemistry 13
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 37
• Magnetic Resonance Imaging 155
• Machine Learning 198
• Deep Learning 42
• Cohort Studies 501
• Genome-Wide Association Study 74

• Integrated Lipidomic and Energy Metabolomic Analyses Reveal the Cardioprotective Mechanisms of Meconopsis horridula Alkaloids in Heart Failure.

  J Proteome Res, 2026. nov.

• Paired metabolomics identify associations between fecal and serum metabolites in cardiovascular-kidney-metabolic syndrome.

  Front Endocrinol (Lausanne), 2026. okt.

• Targeting Metabolic Drivers of Cardiovascular Disease: Insights for Therapeutic Innovation.

  Drug Des Devel Ther, 2026. okt.

• Impact of matched samples on domain harmonization in cross-cohort NMR metabolomics.

  Metabolomics, 2026. okt.

• Metabolomic biomarkers and metabolic remodelling in genetically characterised hypertrophic cardiomyopathy: a systematic review.

  Metabolomics, 2026. okt.

• Multi-omics profiling reveals coordinated metabolic and immuno-inflammatory remodeling in a high-fat diet and single-dose streptozotocin-induced mouse model of diabetic cardiomyopathy.

  BMC Cardiovasc Disord, 2026. szept.

• Co-Enrichment of Desulfovibrio and Erysipelotrichaceae and Dysregulation of Multiple Amino Acid Pathways in HFpEF: Insights into TXG-Associated Metabolic Changes.

  Int J Mol Sci, 2026. szept.

• Fatty Acid and Oxylipin Metabolism Differentiate Isolated Postcapillary From Combined Pre- and Postcapillary Pulmonary Hypertension.

  Circ Heart Fail, 2026. szept.

• Reversing the pipeline: a 'human-first' multi-omics approach to cardiovascular discovery.

  Exp Mol Med, 2026. szept.

• Metabolomic Profiling Delineates Stage-Associated Metabolic Remodelling in Cardiovascular-Kidney-Metabolic Syndrome.

  Diabetes Metab Res Rev, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.